Peptide Supplier SLA Design: Lead Time, COA Delivery, and Service Credits That Actually Work

B2B Sourcing | 2026-07-09 | 9 min read

How to design a peptide supplier SLA that is enforceable, with lead time targets, COA delivery windows, deviation notification timelines, and service credit mechanics that incentivize the right behavior.

Why most peptide supplier SLAs do not work

A typical peptide SLA is a one-page document with "lead time 14 days" and "COA delivered with shipment" written into a contract that nobody reads again. The problem is not the targets — they are usually reasonable. The problem is that there is no enforcement mechanism, no measurement system, and no consequence for missing them.

A working SLA has four ingredients:

  • Targets that are measurable
  • A measurement system that runs continuously
  • A consequence that is meaningful to both sides
  • A review cadence that catches drift before it becomes a pattern

Skip any one of them and the SLA is wallpaper.

The five SLAs every peptide contract should include

| SLA | Target | Measurement | | --- | --- | --- | | Lead time | 7-14 days catalog, 25-45 days custom | Time from PO release to shipment | | COA delivery | Same day as shipment, always before acceptance | Time from shipment to COA delivery | | Deviation notification | Within 24 hours of internal detection | Time from detection to buyer notification | | Replacement lot | 14-21 days for COA failure | Time from buyer refusal to replacement dispatch | | Customer response | Within 1 business day on RFQ and quotes | Time from inquiry to first response |

A contract that omits any of these five is missing a real risk.

SLA 1 — Lead time

Lead time is the most-discussed and least-enforced SLA. The reason: it depends on too many variables to score with a single metric.

Define lead time precisely:

  • Trigger event: PO release date, forecast acceptance date, or payment confirmation date
  • Endpoint: shipment hand-off to carrier
  • Exclusions: buyer-caused delays, force majeure, custom synthesis

The service credit for a missed lead time should be 1-3% of the affected release value. Higher credits push the supplier to "manage" lead time, which usually means dropping quality or pushing the order to a different lot.

SLA 2 — COA delivery

COA delivery is the easiest SLA to measure and enforce. Two timestamps:

  • Shipment hand-off
  • COA delivery to the buyer

A COA delivered after the shipment, or worse, after the buyer's acceptance review, breaks the buyer's quarantine workflow. Service credit should be 2-5% of the affected release value, with a credit cap at the full release value if the COA is more than 5 business days late.

SLA 3 — Deviation notification

Deviation notification is the hardest SLA to enforce because it depends on the supplier's self-reporting. Three mechanisms help:

  • A standing definition of "deviation" in the quality agreement
  • A 24-hour notification deadline from internal detection
  • A buyer's right to suspend release on any deviation

Service credit for a missed deviation notification should be 3-5% of the affected release value, with a higher credit (or right to terminate) if the deviation is undisclosed and surfaces only after a buyer complaint.

SLA 4 — Replacement lot

When a lot fails acceptance, the buyer needs a replacement. The SLA should pin down:

  • Lead time from buyer refusal to replacement dispatch
  • Cost allocation (supplier pays if the failure was supplier-caused, buyer pays if it was buyer-caused)
  • Pricing protection on the replacement lot
  • Documentation scope for the replacement lot

Service credit for a missed replacement lead time should be 2-4% of the replacement release value, plus expedited shipping at the supplier's cost.

SLA 5 — Customer response

Customer response is a soft SLA but easy to enforce. Two metrics:

  • Time from RFQ receipt to first response (target: 1 business day)
  • Time from buyer question to supplier answer (target: 1 business day for routine, 3 for technical)

Service credits here are usually nominal (1% of monthly contract value) but they signal seriousness. A supplier that misses customer response SLAs is usually missing the harder ones too.

Service credit mechanics that work

Three mechanics make service credits enforceable:

  • **Automatic application** — credits are issued on the next invoice, no dispute required
  • **Cumulative cap** — total credits capped at 10-15% of annual contract value to keep the supplier solvent
  • **Review trigger** — a quarterly SLA review where the supplier and buyer look at trends, not just totals

Service credits that require a dispute, lack a cap, or are reviewed annually usually fail to change behavior.

What to do when SLAs are repeatedly missed

The escalation ladder should be defined in the contract:

  • First miss — service credit issued
  • Second consecutive miss in same SLA — formal root cause analysis
  • Third miss in rolling 12 months — corrective action plan with timeline
  • Fourth miss — right to terminate for cause

Without this ladder, the only lever is termination, which is too big a hammer for a recurring problem.

Common SLA design mistakes

  • Targets that are unrealistic (lead time 3 days for custom synthesis)
  • Credits that are too small to matter (0.1% of release value)
  • Credits that are too large to be paid (50% of release value)
  • Missing cumulative cap
  • No review cadence
  • Targets measured in supplier-favorable terms (calendar days instead of business days)

How ZePeptide structures SLAs

ZePeptide baseline SLA structure:

  • Lead time: 7-14 days catalog, 25-45 days custom
  • COA delivery: same day as shipment, secure portal delivery
  • Deviation notification: 24 hours from internal detection
  • Replacement lot: 14-21 days, supplier cost if supplier-caused
  • Customer response: 1 business day on RFQ and quote questions

Service credit structure: 1-5% per missed SLA, cumulative cap at 10% of annual contract value, quarterly review. Talk to the B2B team to scope the SLA for your program.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.